The mission of the OSUCCC Real Time PCR Shared Resource (RT PCR SR) is to advance the quality of cancer research while increasing productivity of OSUCCC members at reduced costs through providing high quality instrumentation and expert resources. Quantitative real time polymerase chain reaction (QRT-PCR) provides a rapid and accurate method for determination of levels of specific DNA and RNA sequences from tissue samples. It is based on detection of a fluorescent signal produced proportionately during amplification of a PCR product. However, current technology is associated with high costs for reagents, instrumentation, setup, erroneous design/data interpretation and maintenance. For this reason, QRT-PCR expertise and instrumentation are made available to OSUCCC investigators as well as to OSU researchers at large through the RT PCR. The Applied Biosystem's Prism 7700 instrument and expert personnel are located in the Tzagournis Medical Research Facility (TMRF) that is at the center of the OSU Medical Center complex. Over the past two years since this was transitioned from a developmental to a full SR, 52 members, representing 6 of the 60SUCCC Programs, have used the resource, making up >82% of the overall RT PCR usage. To meet the needs of and to ensure the RT PCR SR is accessible to all OSUCCC members, nine services in addition to instrument self-service and training have been added: consultations, primer/probe design, technicianperformed service, aid in developing grants pertaining to Real Time PCR, a website for convenient on-line scheduling and a database of optimized Real Time PCR primers, data analysis/interpretation, data archiving and an in-house store of common reagents and disposables. Based on grants funded in the last year, grants in review, and grants to be submitted in the next year, the current projection in usage of the RT PCR SR's main facility by OSUCCC members is an increase of greater than 2.5 times the current usage. To meet and exceed the RT PCR SR's main goals to increase productivity in a cost-effective manner and advance the quality of cancer research by OSUCCC members, some cost sharing for instrumentation upgrades and new services are proposed.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016058-34
Application #
7743482
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
2010-11-30
Budget Start
2008-12-01
Budget End
2010-11-30
Support Year
34
Fiscal Year
2009
Total Cost
$72,166
Indirect Cost
Name
Ohio State University
Department
Type
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Ozawa, Patricia Midori Murobushi; Alkhilaiwi, Faris; Cavalli, Iglenir João et al. (2018) Extracellular vesicles from triple-negative breast cancer cells promote proliferation and drug resistance in non-tumorigenic breast cells. Breast Cancer Res Treat 172:713-723
Ngankeu, Apollinaire; Ranganathan, Parvathi; Havelange, Violaine et al. (2018) Discovery and functional implications of a miR-29b-1/miR-29a cluster polymorphism in acute myeloid leukemia. Oncotarget 9:4354-4365
Lopez, Cecilia M; Yu, Peter Y; Zhang, Xiaoli et al. (2018) MiR-34a regulates the invasive capacity of canine osteosarcoma cell lines. PLoS One 13:e0190086
Victor, Aaron R; Weigel, Christoph; Scoville, Steven D et al. (2018) Epigenetic and Posttranscriptional Regulation of CD16 Expression during Human NK Cell Development. J Immunol 200:565-572
Lampis, Andrea; Carotenuto, Pietro; Vlachogiannis, Georgios et al. (2018) MIR21 Drives Resistance to Heat Shock Protein 90 Inhibition in Cholangiocarcinoma. Gastroenterology 154:1066-1079.e5
Le Gallo, Matthieu; Rudd, Meghan L; Urick, Mary Ellen et al. (2018) The FOXA2 transcription factor is frequently somatically mutated in uterine carcinosarcomas and carcinomas. Cancer 124:65-73
Jones, Jeffrey A; Mato, Anthony R; Wierda, William G et al. (2018) Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol 19:65-75
Baldassari, Federica; Zerbinati, Carlotta; Galasso, Marco et al. (2018) Screen for MicroRNA and Drug Interactions in Breast Cancer Cell Lines Points to miR-126 as a Modulator of CDK4/6 and PIK3CA Inhibitors. Front Genet 9:174
Yang, Xiaosong; Pan, You; Qiu, Zhaojun et al. (2018) RNF126 as a Biomarker of a Poor Prognosis in Invasive Breast Cancer and CHEK1 Inhibitor Efficacy in Breast Cancer Cells. Clin Cancer Res 24:1629-1643
Latchana, Nicholas; DiVincenzo, Mallory J; Regan, Kelly et al. (2018) Alterations in patient plasma microRNA expression profiles following resection of metastatic melanoma. J Surg Oncol 118:501-509

Showing the most recent 10 out of 2602 publications